Fox Chase Cancer Center News

Edna Cukierman, PhD
February 19, 2020

Fox Chase Researchers Lend Expertise to Consensus Statement on Cancer-Associated Fibroblasts

PHILADELPHIA (February 19, 2020) – Edna Cukierman and Igor Astsaturov were among a group of almost 30 experts convened to discuss the current understanding of CAFs.

February 18, 2020

New Drug Target Identified for High-Grade Serous Ovarian Cancer

PHILADELPHIA (February 18, 2020) – In a study published today, researchers at Fox Chase Cancer Center have identified a new kinase target for the treatment of high-grade serous ovarian cancer that has the potential to lead to the development of new drugs.

February 14, 2020

Cukierman Named Fellow of the American Gastroenterological Association

PHILADELPHIA (February 14, 2020) – Dr. Cukierman's induction as a fellow is notable because historically AGA has been a medical association. Cukierman is not a medical doctor, but she joined AGA in order to better understand the medical side of gastroenterology.

February 13, 2020

Fox Chase Featured as Cancer Center of Excellence in One of Journal of Oncology Practice’s Most-Read 2019 Articles

PHILADELPHIA (February 13, 2020) – A research article featuring featured Fox Chase Cancer Center  was awarded the 2019 Journal of Oncology Practice (JOP) Editor’s Pick Award for being one of the top five most-read articles published in JOP in 2019.

February 10, 2020

Gene May Play Bigger Role in Kidney Cancer Than Previously Thought

PHILADELPHIA (February 10, 2020)—Its involvement in causing over 50 percent of all cancers makes p53 one of the most well-known cancer genes. But there are some malignancies, like kidney cancer, that rarely have p53 mutations.

February 5, 2020

Expanded Database Should Allow Easier Access to Information on Protein Interactions

PHILADELPHIA (February 5, 2020) –Roland L. Dunbrack Jr., PhD, director of the Molecular Modeling Facility at Fox Chase Cancer Center, and his team have updated their Protein Common Interface Database (ProtCID) to include data on the individual domain level, which greatly increases the number of large protein-protein clusters available in the database.


The ANCC accreditation will last until May 2023, at which point the program will need to apply for re-accreditation.
February 4, 2020

Fox Chase Cancer Center Earns Accreditation From American Nurses Credentialing Center

PHILADELPHIA (February 4, 2020) – Fox Chase Cancer Center has announced that its Nurse Residency Program achieved ANCC Practice Transition Accreditation with Distinction, the highest recognition awarded.

 “There were four institutions who participated in this trial, enrolling 20 patients in less than six months, showing that these types of studies can be accomplished in a relatively short period of time.”
February 3, 2020

IGF-1R a Marker for, but Not Driving Wild-Type GIST

PHILADELPHIA (February 3, 2020) – Although insulin-like growth factor receptor-1 (IGF-R1) is a biomarker for wild-type gastrointestinal stromal tumors (GIST), these mutations do not appear to be driving the disease, according to the results of a study from researchers at Fox Chase Cancer Center.


Connect with Fox Chase